Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced a new collaboration with Viatris, a global healthcare company, to make 17 of its established brand medications more affordable for consumers. Beginning today, eligible commercially insured patients may pay as low as $0–$4 on select Viatris medications through GoodRx. Cash-paying consumers, regardless of insurance status, can use GoodRx to access discounted cas.

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced employer-sponsored access to Zepbound® (tirzepatide) KwikPen® (for single-patient-use) through GoodRx Employer Direct. As one of Lilly's Employer Connect independent program administrators, GoodRx enables self-insured employers to access Zepbound KwikPen at a set price of $449 across all doses, with the flexibility to further subsidize the cost for employees a.

GoodRx Holdings, Inc. (GDRX) Q4 2025 Earnings Call Transcript

The prescription experience has started to resemble other parts of digital commerce: shoppers want clear pricing, fewer handoffs and a quicker path from decision to fulfillment. That push toward self-service framed GoodRx's fourth-quarter earnings discussion Thursday (Feb.

While the top- and bottom-line numbers for GoodRx (GDRX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading platform for medication savings in the U.S., has released its financial results for the fourth quarter and full year of 2025. Fourth Quarter 2025 Highlights Revenue of $194.8 million Net income of $5.4 million; Net income margin of 2.8% Adjusted Net Income1 of $29.0 million; Adjusted Net Income Margin1 of 14.9% Adjusted EBITDA1 of $65.0 million; Adjusted EBITD.

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced the launch of GoodRx Employer Direct. The new offering enables employers to directly lower the cost of high-impact brand medications, including GLP-1s, by applying targeted subsidies to discounted cash prices from pharmaceutical manufacturers. Employers can also deploy branded versions of GoodRx's condition-specific telemedicine solutions, integrating clinical.